EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma.

Authors

Patrick Roth

Patrick Roth

University Hospital Zurich, Zurich, Switzerland

Patrick Roth , Jaap C. Reijneveld , Thierry Gorlia , Frederic Dhermain , Filip Yves Francine Leon De Vos , Maureen Vanlancker , Christopher J. O'Callaghan , Emilie Le Rhun , Martin J. Van Den Bent , Warren P. Mason , Michael Weller

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Central Nervous System Tumors

Track

Central Nervous System Tumors

Sub Track

Central Nervous System Tumors

Clinical Trial Registration Number

NCT03345095

Citation

J Clin Oncol 37, 2019 (suppl; abstr TPS2072)

DOI

10.1200/JCO.2019.37.15_suppl.TPS2072

Abstract #

TPS2072

Poster Bd #

260b

Abstract Disclosures